Breast Cancer Clinical Trial
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Summary
To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung cancer (SCLC), bladder cancer (BC), and ovarian cancer (OC). A combination of nivolumab with ipilimumab and cobimetinib is also investigated in PC.
Full Description
All tumor types are now closed for enrollment:
Triple Negative Breast Cancer
Gastric Cancer
Pancreatic Cancer
Small Cell Lung Cancer
Bladder Cancer
Ovarian Cancer
Eligibility Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Subjects with histologically or cytologically confirmed locally advanced or metastatic disease of the following tumor types:
Triple Negative Breast Cancer
Gastric Cancer
Pancreatic Cancer
Small Cell Lung Cancer
Bladder Cancer
Ovarian Cancer
Subjects must have measurable disease
Eastern Cooperative Oncology Group (ECOG) of 0 or 1
Adequate hematological and organ function as confirmed by laboratory values
Exclusion Criteria:
Active brain metastases or leptomeningeal metastases
Subjects with active, known or suspected autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of treatment
Prior therapy with experimental anti-tumor vaccines; any T cell co-stimulation or checkpoint pathways, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, including Ipilimumab; or other medicines specifically targeting T cell is also prohibited
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 37 Locations for this study
Muscle Shoals Alabama, 35661, United States
Aurora Colorado, 80045, United States
New Haven Connecticut, 06520, United States
Gainesville Florida, 32610, United States
Tampa Florida, 33612, United States
Atlanta Georgia, 30322, United States
Baltimore Maryland, 21287, United States
Boston Massachusetts, 02215, United States
Boston Massachusetts, 02215, United States
Omaha Nebraska, 68130, United States
Mineola New York, 11501, United States
New York New York, 10065, United States
Charlotte North Carolina, 28204, United States
Durham North Carolina, 27710, United States
Portland Oregon, 97239, United States
Franklin Tennessee, 37067, United States
Nashville Tennessee, 37232, United States
Houston Texas, 77030, United States
Seattle Washington, 98104, United States
Toronto Ontario, M5G 2, Canada
Copenhagen , 2100, Denmark
Helsinki Uusimaa, 00290, Finland
Tampere , 33521, Finland
Bonn , 53105, Germany
Frankfurt , 60488, Germany
Heidelberg , 69120, Germany
Kassel , 34125, Germany
Bologna , 40138, Italy
Milano , 20133, Italy
Napoli , 80131, Italy
Padova , 35128, Italy
Barcelona , 08036, Spain
Madrid , 28040, Spain
Madrid , 28041, Spain
Madrid , 28050, Spain
London Greater London, SW3 6, United Kingdom
Glasgow Lanarkshire, G12 0, United Kingdom
Sutton Surrey, SM2 5, United Kingdom
How clear is this clinincal trial information?